

I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- invasive breast cancer confirmed by biopsy - tumor is at least 2.5 cm in size - no prior chemotherapy for this cancer - no restrictions in activity or partially restricted with work, but able to independently care for self - willing to have another breast biopsy - not pregnant or breast feeding - consult study staff for additional requirements

Exclusion Criteria:

- other medical or mental health diagnosis that would limit compliance with study requirements

Conditions & Interventions

Interventions:

Drug: ABT-888, Drug: AMG 386 and Trastuzumab, Drug: AMG 386 with or without Trastuzumab, Drug: AMG 479 (Ganitumab) plus Metformin, Drug: ARV-471, Drug: ARV-471 + Abemaciclib, Drug: ARV-471 + Letrozole, Drug: ARX788, Drug: ARX788 + Cemiplimab, Drug: Amcenestrant, Drug: Amcenestrant + Abemaciclib, Drug: Amcenestrant + Letrozole, Drug: Cemiplimab, Drug: Cemiplimab plus REGN3767, Drug: Dan222 + Niraparib, Drug: Datopotamab deruxtecan, Drug: Datopotamab deruxtecan + Durvalumab, Drug: Durvalumab plus Olaparib, Drug: Endoxifen + Abemaciclib, Drug: Ganetespi, Drug: Lasofofifene, Drug: MK-2206 with or without Trastuzumab, Drug: Neratinib, Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Drug: PLX3397, Drug: Patritumab and Trastuzumab, Drug: Pembrolizumab - 4 cycle, Drug: Pembrolizumab - 8 cycle, Drug: Pertuzumab and Trastuzumab, Drug: Rilvegostomig + TDXd, Drug: SD-101 + Pembrolizumab, Drug: SGN-LIV1A, Drug: SYD985 (vic-]trastuzumab duocarmazine), Drug: Sarilumab + Cemiplimab + Paclitaxel, Drug: Standard Therapy, Drug: T-DM1 and Pertuzumab, Drug: Talazoparib plus Irinotecan, Drug: Trilaciclib with or without trastuzumab + pertuzumab, Drug: Tucatinib plus trastuzumab and pertuzumab, Drug: VV1 + Cemiplimab, Drug: Z-endoxifen, Drug: Zanidatamab

Conditions:

Cancer

Keywords:

Breast Cancer, Breast Tumors, I-SPY, ISPY, ISPY2, Clinics and Surgery Center (CSC)

More Information

Description: The I-SPY2 study uses 10 years of results to help your doctor understand more about your tumor and how to classify it better. This means your doctor will have more information and might be able to offer you a new treatment that could work better than the usual treatments. We need better treatments and better ways to identify which patients will benefit most from particular treatments.

Study Contact: Douglas Yee - yeex006@umn.edu

Principal Investigator: Douglas Yee, MD

Phase: PHASE2

IRB

Number: STUDY00011111

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.